Viewing Study NCT00982657



Ignite Creation Date: 2024-05-05 @ 9:52 PM
Last Modification Date: 2024-10-26 @ 10:10 AM
Study NCT ID: NCT00982657
Status: TERMINATED
Last Update Posted: 2015-11-20
First Post: 2009-09-22

Brief Title: A Trial Of CVX-060 An Anti-Angiogenic COVX-Body In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Sponsor: Pfizer
Organization: Pfizer

Study Overview

Official Title: A Phase Ibii Multicenter Trial Of Cvx-060 A Selective Angiopoietin-2 Ang-2 Binding Anti-angiogenic Covx-body In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Status: TERMINATED
Status Verified Date: 2015-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Refer to statement in Summary SectionDetailed Description
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The safety and tolerability of CVX-060 have been established in the first-in-human clinical trial CVX-060-101 Thus this phase IbII trial is to assess the safety and pharmacokinetics PK profiles of combining CVX-060 with sunitinib in patients with advanced solid tumors and to subsequently assess the treatment efficacy of the combination treatment as well as that of sunitinib alone in patients with advanced renal cell carcinoma mRCC
Detailed Description: On 23-Nov-2010 B1131001 CVX-060-102 was closed to enrollment due to emerging clinical data which led to a re-assessment of the strategic goals of the PF-04856884 program The study enrolled the Phase 1b portion only Subsequently on 25-Oct-2012 due to data safety signals in a separate clinical trial with PF-04856884 CVX-060 all PF-04856884 studies were discontinued and ongoing patients on B1131001 were permitted to remain on study at a reduced PF-04856884 dose if determined to have been deriving clinical benefit

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2010-022657-42 EUDRACT_NUMBER Alias Study Number None
CVX-060-102 OTHER None None